Many breast cancer patients don't get treatment for heart problems

American Heart Association meeting report abstract 280

2014-06-03

(Press-News.org) Only a third of older breast cancer patients saw a cardiologist within 90 days of developing heart problems, in a study presented at the American Heart Association's Quality of Care and Outcomes Research 2014 Scientific Sessions.

Breast cancer patients with heart problems who saw a cardiologist were more likely to receive standard therapy for their heart failure than those who did not see a heart specialist, the study found.

"The majority of older women who develop heart problems after their breast cancer therapy aren't treated by a cardiologist, and they had lower quality of care," said Jersey Chen, M.D., M.P.H., lead author of the study and a research scientist and cardiologist at Kaiser Permanente in Rockville, Maryland. "This suggests that this is an important area for oncologists and cardiologists to collaborate."

For the study, researchers used a Medicare-linked database to identify women older than 65 who were diagnosed in 2000-09 with stage I-III breast cancer and received cancer treatments that previously had been linked to heart problems.

The study tracked which patients developed cardiomyopathy or heart failure. Cardiomyopathy is a weakening of the heart and its ability to pump blood. Heart failure occurs when the weakened heart causes symptoms such as fatigue and shortness of breath.

Among 8,400 breast cancer patients treated with either chemotherapy drugs called anthracyclines or a targeted therapy called trastuzumab, 1,028 — about 12 percent — developed heart problems within three years, and 345 (34 percent) saw a cardiologist within 90 days of their heart diagnosis. Women with heart failure after cancer treatment were more likely to be treated with standard medications if seen by a cardiologist compared with those who did not see a cardiologist.

"The bottom line is, if you have breast cancer and you're treated with anthracyclines or trastuzumab, you should know they have side effects," Chen said. "And if you have symptoms of heart problems like shortness of breath or swelling in the feet or legs, seek attention quickly, preferably with doctors familiar and comfortable with treating heart failure after cancer therapy."

"Many cancer patients who develop heart failure or cardiomyopathy aren't getting the necessary medications, regardless of whether they're seen by cardiologists," he said. "So there is work to be done to improve care for all women with cardiac complications after cancer therapy."

Using 2006-11 data from Medicare's Part D drug benefit, the study found that 60 percent of patients with heart problems who saw a cardiologist received ACE inhibitors or angiotensin receptor blockers, versus 44 percent of those who didn't see a cardiologist. For beta-blockers, the figures were 40 percent versus 24 percent. Those drugs are the mainstay of treatment for heart failure, Chen said.

People with other cancers — especially if they're older or have many other health problems — should also be vigilant for heart symptoms if they receive anthracyclines or trastuzumab, Chen said.

INFORMATION: Co-authors are Jessica Long, M.P.H.; Carol Chen, M.D.; Shi-yi Wang, Ph.D.; Richard Steingart, M.D.; and Cary P. Gross, M.D. Author disclosures are on the abstract.

A three-year American Heart Association grant funded the study.

Additional Resources: About Heart Failure What is Cardiomyopathy in Adults? Researcher photo, heart illustration, and beating heart animation are available on the right column of this news release link http://newsroom.heart.org/news/many-breast-cancer-patients-dont-get-treatment-for-heart-problems?preview=38c4740875cf28b73a896a1d05a6f002 Follow AHA/ASA news on Twitter @HeartNews #QCOR14.

NOTE: Presentation is 4:30 p.m. CT/5:30 p.m. ET Tuesday, June 3, 2014.

Statements and conclusions of study authors presented at American Heart Association scientific meetings are solely those of the study authors and do not necessarily reflect the association's policy or position. The association makes no representation or guarantee as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at http://www.heart.org/corporatefunding.

For Media Inquiries: (214) 706-1173

Michael Burton: (214) 706-1236; michael.burton@heart.org

Cathy Lewis: (214) 706-1324; cathy.lewis@heart.org

Julie Del Barto (broadcast): (214) 706-1330; julie.delbarto@heart.org

For Public Inquiries: (800) AHA-USA1 (242-8721)

http://www.heart.org and http://www.strokeassociation.org

Categories: Scientific Conferences & Meetings

ELSE PRESS RELEASES FROM THIS DATE:

Community program helps lower blood pressure among minorities

2014-06-03

Minorities at a higher risk of developing hypertension used a community-based program to significantly lower their blood pressure, researchers said at the American Heart Association's Quality of Care and Outcomes Research 2014 Scientific Sessions. Minorities at a higher risk of developing hypertension used a community-based program to significantly lower their blood pressure, researchers said at the American Heart Association's Quality of Care and Outcomes Research 2014 Scientific Sessions. Researchers assessed the use of the American Heart Association's Check. Change. ...

Implanted heart device linked to increased survival

2014-06-03

DURHAM, N.C. -- Implantable cardioverter defibrillators (ICDs) are associated with improved survival among heart failure patients whose left ventricles only pump 30 to 35 percent of blood out of the heart with each contraction, according to a study from the Duke Clinical Research Institute. The findings, published in the June 4 issue of the Journal of the American Medical Association, support existing recommendations to implant ICDs in patients with a left ventricular ejection fraction (LVEF) – a measurement of how much blood is squeezed out of the heart – of 35 percent ...

High risk of recurrence of 2 life-threatening adverse drug reactions

2014-06-03

Individuals who are hospitalized for the skin conditions of Stevens-Johnson syndrome and toxic epidermal necrolysis appear to have a high risk of recurrence, according to a study in the June 4 issue of JAMA. Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening conditions that develop primarily as responses to drugs, and result in extensive epidermal detachment (upper layers of the skin detach from the lower layers). Recurrence has been reported in isolated cases, and the overall risk of recurrence has been unknown, according to background ...

Outcomes for older adults with pneumonia who receive treatment including azithromycin

2014-06-03

In a study that included nearly 65,000 older patients hospitalized with pneumonia, treatment that included azithromycin compared with other antibiotics was associated with a significantly lower risk of death and a slightly increased risk of heart attack, according to a study in the June 4 issue of JAMA. Pneumonia and influenza together are the eighth leading cause of death and the leading causes of infectious death in the United States. Although clinical practice guidelines recommend combination therapy with macrolides (a class of antibiotics), including azithromycin, ...

Preventive placement of ICDs for less severe heart failure may improve survival

2014-06-03

An examination of the benefit of preventive placement of implantable cardioverter-defibrillators (ICDs) in patients with a less severe level of heart failure, a group not well represented in clinical trials, finds significantly better survival at three years than that of similar patients with no ICD, according to a study in the June 4 issue of JAMA. Although clinical trials have established the ICD as the best currently available therapy to prevent sudden cardiac death in patients with heart failure, some uncertainties remain regarding preventive use of ICDs in patients ...

Study: New test predicts if breast cancer will spread

2014-06-03

June 3, 2014 – BRONX, NY – The study was led by researchers at the National Cancer Institute (NCI)─designated Albert Einstein Cancer Center of Albert Einstein College of Medicine of Yeshiva University and Montefiore Einstein Center for Cancer Care and was published online today in the Journal of the National Cancer Institute (JNCI). "Tests assessing metastatic risk can help doctors identify which patients should receive aggressive therapy and which patients should be spared," said Thomas Rohan, M.D., Ph.D., the lead and corresponding author of the study and professor ...

Deeper than ancestry.com, 'EvoCor' identifies gene relationships

2014-06-03

A frontier lies deep within our cells. Our bodies are as vast as oceans and space, composed of a dizzying number of different types of cells. Exploration reaches far, yet the genes that make each cell and tissue unique have remained largely obscure. That's changing with the help of a team led by Gregorio Valdez, an assistant professor at the Virginia Tech Carilion Research Institute. Valdez and his team designed a search engine – called EvoCor – that identifies genes that are functionally linked. The name, a portmanteau of "evolution" and "correlation," points to ...

New definition of kidney disease for clinical trials could lead to new treatments

2014-06-03

A new study led by researchers at the Johns Hopkins Bloomberg School of Public Health suggests that new therapies for kidney disease could be developed more quickly by revising the definition of kidney disease progression used during clinical trials. If adopted, the new definition could shorten the length of some clinical trials and also potentially encourage more clinical trials in kidney disease. The findings will be published in the June 3, 2014 online edition of the Journal of the American Medical Association. Chronic kidney disease (CKD) is a worldwide public health ...

2-D transistors promise a faster electronics future

2014-06-03

Faster electronic device architectures are in the offing with the unveiling of the world's first fully two-dimensional field-effect transistor (FET) by researchers with the Lawrence Berkeley National Laboratory (Berkeley Lab). Unlike conventional FETs made from silicon, these 2D FETs suffer no performance drop-off under high voltages and provide high electron mobility, even when scaled to a monolayer in thickness. Ali Javey, a faculty scientist in Berkeley Lab's Materials Sciences Division and a UC Berkeley professor of electrical engineering and computer science, led ...

Investigating unusual three-ribbon solar flares with extreme high resolution

2014-06-03

The 1.6 meter telescope at Big Bear Solar Observatory (BBSO) in California has given researchers unparalleled capability for investigating phenomena such as solar flares. Operated by New Jersey Institute of Technology (NJIT), the BBSO instrument is the most powerful ground-based telescope dedicated to studying the star closest to Earth. On June 2, Distinguished Professor of Physics Haimin Wang joined NJIT colleagues at the 224th meeting of the American Astronomical Society (AAS), held in Boston, Massachusetts, to present intriguing data about solar flares — specifically, ...

LAST 30 PRESS RELEASES:

Innovative risk score accurately calculates which kidney transplant candidates are also at risk for heart attack or stroke, new study finds

Amid record year for dengue infections, new study finds climate change responsible for 19% of today’s rising dengue burden

New study finds air pollution increases inflammation primarily in patients with heart disease

AI finds undiagnosed liver disease in early stages

The American Society of Tropical Medicine and Hygiene and the Bill & Melinda Gates Foundation announce new research fellowship in malaria genomics in honor of professor Dominic Kwiatkowski